Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7250839 | 0.81 | CA12 (0.50) | HPGDALOX15CA12CA1CA2 | |
| SCHEMBL11323212 | 0.78 | ALDH1A1 (0.47) | CYP1A2NPC1RAB9AKCNJ11ALDH1A1 | |
| SCHEMBL799896 | 0.77 | SMN1; SMN2 (0.70) | HPGDALOX15SMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL2093283 | 0.75 | NLRP3 (0.60) | HPGDSMN1; SMN2NLRP3CYP2C9CYP2C19 | |
| SCHEMBL7256712 | 0.75 | GAA (0.56) | HPGDALOX15CA12CA1CA2 | |
| SCHEMBL4173469 | 0.75 | MAPT (0.49) | HPGDALOX15SMN1; SMN2MAOACYP1A2 | |
| SCHEMBL7255889 | 0.74 | HPGD (0.54) | HPGDALOX15CA12CA1CA2 | |
| SCHEMBL31331879 | 0.72 | HPGD (0.69) | HPGDALOX15SMN1; SMN2NLRP3CYP1A2 | |
| SCHEMBL10749929 | 0.72 | HPGD (0.69) | HPGDALOX15SMN1; SMN2NLRP3CYP1A2 | |
| SCHEMBL8652685 | 0.72 | CA12 (0.56) | HPGDALOX15CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES AG (AT) | 2014-11-27 | — | — | US | disclosed |
| EP-2674161-A1 | FMO3 inhibitors for treating pain | Akron Molecules GmbH (AT) | 2013-12-18 | — | — | EP | disclosed |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | AKRON MOLECULES GMBH (AT) | 2013-09-26 | — | — | US | disclosed |
| EP-2637649-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | Akron Molecules GmbH (AT) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012062925-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES GMBH (AT) | 2012-05-18 | — | — | WO | disclosed |
| CN-101951778-A | Use of sulfuryl fluoride as bud inhibitor | DOW AGROSCIENCES LLC | 2011-01-19 | — | — | CN | disclosed |
| EP-2211623-A2 | USE OF SULFURYL FLUORIDE AS A SPROUT INHIBITION AGENT | Dow AgroSciences LLC (US) | 2010-08-04 | — | — | EP | disclosed |
| US-20090124502-A1 | USE OF SULFURYL FLUORIDE AS A SPROUT INHIBITION AGENT | DOW AGROSCIENCES LLC (US) | 2009-05-14 | — | — | US | disclosed |
| WO-2009061862-A2 | USE OF SULFURYL FLUORIDE AS A SPROUT INHIBITION AGENT | DOW AGROSCIENCES LLC (US) | 2009-05-14 | — | — | WO | disclosed |
| WO-2000049877-A1 | BIOLOGICAL CONTROL OF SPROUTING IN POTATOES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 2000-08-31 | — | — | WO | disclosed |
| US-6107247-A | SUPPRESSING SPROUTING OF A POTATO TUBER BY APPLYING A WHOLE CULTURE BROTH OF A BACTERIAL ISOLATE SELECTED FROM SPECIFIED BACTERIA OF PANTOEA, PSEUDOMONAS, OR ENTEROBACTER | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 2000-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | TRPV1, ACHE, OPRL1 | HPGD 424/4885ALOX15 207/4885CA12 687/4885 |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | TRPV1, ACHE, OPRL1 | HPGD 424/4885ALOX15 207/4885CA12 687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.